Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis: comment-Reference-Cited by-同舟云学术

Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis: comment

Published:2014-12-06 Issue:3 Volume:13 Page:485-486
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Cugno M.¹,Tedeschi S.²,Ardissino G.²

Affiliation:

1. Medicina Interna, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti; Università degli Studi di Milano; Fondazione IRCCS Ca' Granda; Ospedale Maggiore Policlinico; Milan Italy

2. Center for HUS Prevention, Control and Management; Fondazione IRCCS Ca' Granda; Ospedale Maggiore Policlinico; Milan Italy

Funder

Alexion Pharmaceuticals, Inc

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jth.12764/fullpdf

Reference6 articles.

1. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome;Cugno;J Thromb Haemost,2014

2. Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis;Wehling;J Thromb Haemost,2014

3. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy;Noris;Blood,2014

4. Complement activation patterns in atypical hemolytic uremic syndrome during acute phase and in remission;Volokhina;Clin Exp Immunol,2014

5. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases;Ardissino;Am J Kidney Dis,2014

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eculizumab treatment in atypical hemolytic uremic syndrome: correlation between functional complement tests and drug levels;Journal of Nephrology;2022-01-11

2. Genetic and molecular evidence for complement dysregulation in patients with HELLP syndrome;Thrombosis Research;2020-12

3. Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab;Clinical Pharmacokinetics;2019-02-13

4. Haploidentical Hematopoietic Stem Cell Transplant Complicated by Atypical Hemolytic Uremic Syndrome and Kidney Transplant From the Same Donor With No Immunosuppression but C5 Inhibition;Transplantation;2019-02

5. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use;Pediatric Nephrology;2018-11-06